Infliximab for the treatment of Crohn's disease: Efficacy, safety and pharmacoeconomics

Canadian Journal of Clinical Pharmacology

Volumn 8, Issue 4, 2001, Pages 188-198

  Feagan, Brian G ^a,h   Enns, Robert ^b   Fedorak, Richard N ^c   Panaccione, Remo ^d   Paré, Pierre ^e   Steinhart, A Hillary ^f   Wild, Gary ^g  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h Queen's Cancer Research Institute   (Canada)

Author keywords

Crohn's disease; Fistulizing Crohn's disease; Infliximab; Pharmacoeconomic analysis

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BUDESONIDE; CIPROFLOXACIN; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; SALAZOSULFAPYRIDINE;

ADULT; ANUS FISTULA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; CROHN DISEASE; DAILY LIFE ACTIVITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

EID: 0035688879     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Epidemiology and the natural course of inflammatory bowel disease
2. The epidemiology of inflammatory bowel disease: A large, population-based study in Sweden
3. Inflammatory bowel disease in Northern Alberta, an epidemiologic study
4. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: A population-based study
5. Role of cytokines in the pathogenesis of inflammatory bowel disease
6. A role for TNK-alpha and mucosal T helper-I cytokines in the pathogenesis of Crohn's disease
7. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease
8. Cytokine function: A study in biologic diversity
9. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation
10. Tumor necrosis factor alpha antibody (Infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
11. Approaches to management
12. Medical management of perianal Crohn's disease
13. An audit of stricturoplasty for small-bowel Crohn's disease
14. Surgical options in the management of perianal Crohn's disease
15. Infliximab for the treatment of fistulas in patients with Crohn's disease
16. An evaluation of the utility measurement in Crohn's Disease
17. Incidence and prevalence of ulcerative colitis and Crohn's disease in the county of Copenhagen
18. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease
19. Methotrexate for the treatment of Crohn's disease
20. Measurement of health state utilities for economic appraisal, a review
21. Foundations of cost-effectiveness analysis for health and medical practices
22. Variations in patient utilities for outcomes of the management of chronic stable angina
23. Measurement of quality of life in end-stage renal disease: The time trade-off approach
24. A comparison of methotrexate with placebo for the maintenance of remission of Crohn's disease
25. National cooperative Crohn's disease study: Results of drug treatment
26. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial
27. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial
28. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease
29. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease
30. Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables
31. Double blind, placebo controlled trial of metronidazole in Crohn's disease
32. Metronidazole therapy for Crohn's disease and associated fistulae
33. European cooperative Crohn's disease study (ECCDS): Results of drug treatment
34. A comparison of budesonide with prednisolone for active Crohn's disease
35. National Cooperative Crohn's Disease Study: Adverse reactions to study drugs
36. Oral budesonide for active Crohn's disease
37. Frequency of glucocorticoid resistance and dependency in Crohn's disease
38. Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose-ranging study
39. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study
40. Azathioprine and 6-mercaptopurine in Crohn's disease: A meta-analysis
41. A controlled double blind study of azathioprine in the management of Crohn's disease
42. Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease
43. Outcome of first-trimester exposure to low-dose methotrexate in eight patients with rheumatic disease
44. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity
45. Cyclosporine has no proven role as a therapy for Crohn's disease
46. Low-dose cyclosporine for the treatment of Crohn's disease
47. Efficacy of cyclosporine in treatment of fistula of Crohn's disease
48. Natural course of Crohn's disease after ileocolic resection: Endoscopically visualized ileal ulcers preceding symptoms
49. Recurrence of Crohn's disease after resection
50. Long-term follow-up of stricturoplasty in Crohn's disease
51. Natural history of stricturoplasty in Crohn's disease: 9-Year experience
52. Setons in the surgical management of fistula in ano
53. Inflammatory bowel disease: Cost-of-illness
54. Annual cost of care for Crohn's disease patients: A claims-based cost of illness evaluation
55. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort
56. Inflammatory bowel disease: Health care and costs in Sweden in 1994
57. Antitumor necrosis factor therapy of inflammatory bowel disease: A review of agents, pharmacology, clinical result and safety
58. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
59. Review article: Targeting TNF alpha as a key cytokine in the inflammatory processes of Crohn's disease - The mechanisms of action of infliximab
60. Development of a Crohn's disease activity index
61. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
62. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
63. Clinical experience with infliximab therapy in 100 Crohn's disease patients
64. Infliximab in Crohn's disease: First anniversary clinical experience
65. Successful management of Crohn's disease of the ileoanal pouch with infliximab
66. Review article: Safety of infliximab in clinical trials
67. Long-term follow-up of patients treated with infliximab (anti-TNFα antibody) in clinical trials
68. The relationship between infliximab treatment and lymphoma in Crohn's disease
69. The incidence of non-Hodgkin's lymphoma in hospitalized Crohn's disease patients in Virginia - An administrative database study
70. Infliximab
71. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease
72. Etiology and mechanisms of drug-induced lupus
73. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
74. Estimating the cost-effectiveness of infliximab for Crohn's disease
75. Estimating the cost-effectiveness of infliximab for Crohn's disease
76. Willingness to pay for a quality-adjusted life year: In search of a standard